Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts - Wikidata - awgldk - TriplyDB

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

http://www.wikidata.org/entity/Q35928910

about

Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity Genetics, pathogenesis and clinical interventions in type 1 diabetes The role of TNF-α in mice with type 1- and 2- diabetes In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response.Creating transplant tolerance by taming adverse intragraft innate immunity.Hand transplants and the mandate for tolerance.Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease.Central role for interleukin-2 in type 1 diabetes.Thinking bedside at the bench: the NOD mouse model of T1DM.Contrasting Roles of Islet Resident Immunoregulatory Macrophages and Dendritic Cells in Experimental Autoimmune Type 1 Diabetes.Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.Regulatory T Cell Immunotherapy in Immune-Mediated Diseases Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts.Beta-cell mass and type 1 diabetes: going, going, gone?Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.Recovery from overt type 1 diabetes ensues when immune tolerance and β-cell formation are coupled with regeneration of endothelial cells in the pancreatic islets.Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term triple therapy.2006 Homer W. Smith Lecture: taming T cells Cytokine related therapies for autoimmune disease β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.Anti-inflammatory therapy in type 1 diabetes.MicroRNAs in islet immunobiology and transplantation.Tolerance--is it worth it?The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.T-cell-directed treatment strategies for Type 1 diabetes and the confounding role of inflammation.New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27.Resistance training decreases serum inflammatory markers in diabetic rats.Enhancement of in vitro and in vivo function of agarose-encapsulated porcine islets by changes in the islet microenvironment.A novel mouse model of diabetes mellitus using unilateral nephrectomy.Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse.Introduction: T Cell Trafficking in Inflammation and Immunity.

P2860

Q27008200-010ED260-448E-4510-BE38-2917207BEE1C Q28281029-72698E07-56D6-4FA3-9943-4106E48A1A20 Q28730016-314277D2-44B7-4999-A59D-B6B70727B008 Q28748969-040AE1DB-27A5-46A7-804A-A801E893380B Q30437086-840316D9-4528-4AA7-9CB0-726022512CFE Q33950788-3AE6EEEB-2E2B-472E-8338-9653A6E39AF0 Q34519401-953A5248-80DA-480B-8C8B-837F505AFE67 Q35157382-DF66E611-0143-4478-9216-916F04D72417 Q35587221-D0F240EE-4D61-4DE7-B5C2-1E455345B251 Q35612414-F2F58D5B-1C4E-4F4E-8416-904BE8BC080F Q35911875-A7A628FE-22CD-48AE-8985-74CF951982E3 Q35946260-80EF8433-66AF-49A3-9E46-6CC72F6A5A92 Q36047577-9F83D998-96B2-4067-910B-10A5AFE2FAC1 Q36182476-8B8E8013-0A6E-4A7B-8C3B-F33640E34013 Q36462109-0482069F-E3B9-4A63-A245-F49616186814 Q36906015-A759FCBD-2019-4978-BD5D-0352DCACA271 Q36943672-50FAFDDA-76CE-4497-9A16-5CB06AAEAD1A Q36945031-56E5B05A-5120-4B70-AB1A-C1CC61B1D207 Q37030992-267B6694-DDCC-47A5-8067-EA93537AFFB7 Q37095184-6041A733-F2FB-4207-9055-3A45954A60F3 Q37105565-23B288D0-39BD-45E3-B83E-865D9A660EAF Q37105570-7D664168-0E8C-490F-90BB-D8595BFD52F7 Q37251067-C708A90D-DA09-4180-A1CB-63C84F6A46C0 Q38025979-339C6182-88FB-4394-8CCB-3E2E9ABE1574 Q38163421-78F0BB0D-6C50-4CB9-B3D0-98A3C87EEDCD Q38174023-0B222DCF-913F-43B3-AF8E-E593573BEDE0 Q38424224-F0508EC5-B3BA-4001-82A7-580C821ACD1A Q40485786-FB74DBE9-66FA-497B-B4DA-63E53C2F2A02 Q41762221-663958C3-1DA3-4F47-B50D-FA491491D7F4 Q42012784-08EA43B9-C438-4F46-8556-F2D969DAF533 Q45158247-49A9CD92-B9A9-484E-9A9D-C8474AE1B526 Q45941829-7DFCE20E-AD96-4C6A-B55D-5037C7D99420 Q51018002-08727EFD-C0EB-4C8A-B3BE-64E164286644 Q51318148-83160D44-81D7-46EE-9B7E-86DD20B96890 Q51832369-0A26813E-1AC0-4006-93C3-B68E0C482BFC

P2860

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

http://www.wikidata.org/entity/Q35928910

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@ast

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@en

type

label

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@ast

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@en

prefLabel

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@ast

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@en

P1433

Q35928910-BFCB3C63-D28A-4D18-A19C-B8B156E8E627

P1476

Q35928910-5C9A152F-3D1C-4021-B8DA-ECA6C695B455

P2093

Q35928910-1CFBC5F2-5773-41C0-8A23-BDCAA8406A48

Q35928910-6071DDF4-F8CF-4543-AF7E-09513EE51D54

Q35928910-6AF6AF54-D73D-4ED5-A187-5959BD7BD836

Q35928910-8CA0D519-924A-4A4B-BA3C-680338D906DB

Q35928910-A60CE347-3673-492F-9F3D-22CD54BEC87E

Q35928910-BB653675-5963-4C21-AC61-294A2717EC8B

Q35928910-D7A6E44A-BF80-4B70-A3B8-C4BBD6C65378

Q35928910-E4C6D51D-9F11-40D1-965B-3A0AE214ABED

Q35928910-E4F07366-DF05-46B3-B320-25AE5BCDF8F9

Q35928910-EFC89A5C-BA47-4FDA-AF9C-8E7138BE0DCC

P2860

Q35928910-12D9E382-B8CF-4102-B326-A9237C3511D2

Q35928910-28B6FDD6-29E0-4817-9B6C-41E73B6D72C2

Q35928910-2B8E916C-319F-4246-BD8C-51300EC6789F

Q35928910-2FBAA1D5-70B8-41E2-A9B9-3A2825C74C84

Q35928910-30FA309A-2D76-48E1-A1FA-23CEBBA3CC04

Q35928910-32B3706C-EE07-4A29-B2BD-36604C47DDD9

Q35928910-37327949-0B93-47F8-ADFE-3F0FCE3A18DE

Q35928910-3D5A1953-6415-403A-864F-D13FBFC16673

Q35928910-40F89DD3-123C-41AD-ABD5-07AD550BD418

Q35928910-4B6E67D6-E21F-44FD-8DA8-B08A4FDE4F44

P304

Q35928910-E3E49C91-F800-407D-9DD9-970F85802E85

P31

Q35928910-B8420895-33EC-480E-B237-91ED417CB551

P356

Q35928910-DECF0E36-8C0C-4957-85AB-0E1A3BE862C4

P407

Q35928910-47264A0E-B103-416B-A87A-26222325EBC7

P433

Q35928910-19361EFA-3849-42C3-A1FE-1C6DDA0C3FAE

P478

Q35928910-7A0BD78D-31F8-445C-94E8-24F6C10A81AA

P50

Q35928910-FBD29A91-4278-4C81-AEDA-7BE42597968C

P577

Q35928910-E88A722E-AB90-4E1D-B2A8-646F35570EA4

P5875

Q35928910-A55FD9E9-C1F3-49A7-8F97-7E0D05D71154

P698

Q35928910-45F1CA3D-BCEB-49AA-9F05-CD95EF016E12

P921

Q35928910-E498D055-9660-43DA-AD11-2D6D2C6BE3F3

P932

Q35928910-EED021A7-381B-4031-8B2C-BDA3A37E1BBD

P356

PNAS.0705863104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

@en

P2093

Andi Qipo

http://www.w3.org/2001/XMLSchema#string

Ejona Budo

http://www.w3.org/2001/XMLSchema#string

Hang Shi

http://www.w3.org/2001/XMLSchema#string

Hugh Auchincloss

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Flier

http://www.w3.org/2001/XMLSchema#string

Maria Koulmanda

http://www.w3.org/2001/XMLSchema#string

Prabhakar Putheti

http://www.w3.org/2001/XMLSchema#string

Susan Bonner-Weir

http://www.w3.org/2001/XMLSchema#string

Terry B Strom

http://www.w3.org/2001/XMLSchema#string

Xin Xiao Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

Inflammation and metabolic disorders

An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis.

P304

13074-13079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0705863104

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Degauque

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6168264

http://www.w3.org/2001/XMLSchema#string

P698

17670937

http://www.w3.org/2001/XMLSchema#string

P921

P932

1941818

http://www.w3.org/2001/XMLSchema#string